TITLE

Opportunities Exist to Better Address Management Challenge

AUTHOR(S)
Shames, Lisa; Crosse, Marcia
PUB. DATE
March 2010
SOURCE
GAO Reports;3/23/2010, preceding p1
SOURCE TYPE
Government Document
DOC. TYPE
Article
ABSTRACT
The article discusses the review conducted by the Government Accountability Office (GAO) on the strategic planning and management of the Food and Drug Administration (FDA) in the U.S. It states that the GAO studied the Strategic Action Plan of the FDA which comprises strategies in addressing its management challenges. The GAO also surveyed the managers of the FDA and its other documents. An overview of the recommendations given by the GAO to the FDA is offered.
ACCESSION #
49049216

 

Related Articles

  • FDA Faces Challenges Meeting Its Growing Medical Product Responsibilities and Should Develop Complete Estimates of Its Resource Needs.  // GAO Reports;7/20/2009, preceding p1 

    The article reports on the results of an evaluation conducted by the U.S. Government Accountability Office (GAO) on the ability of the Food and Drug Administration (FDA) in meeting its oversight responsibilities on the safety and efficacy of medical products. GAO examined data on the FDA's...

  • Auditors criticise FDA for failing to track workload and costs. Tanne, Janice Hopkins // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/1/2009, Vol. 339 Issue 7715, p260 

    The article focuses on a report issued by the U.S. Government Accountability Office regarding the failure of the Food and Drug Administration (FDA) to track its workload. The report, which was issued in January 2009, argued that the failure of FDA to track its workload led to its inability to...

  • FDA Update.  // Pharmaceutical Representative;May2010, Vol. 40 Issue 5, p11 

    The article focuses on a report issued by the U.S. Government Accountability Office (GAO) concerning the strategic planning and management of the Food and Drug Administration (FDA).

  • WEEK IN WASHINGTON.  // BioWorld Insight;2/18/2014, Vol. 22 Issue 7, p6 

    The article offers information on the role of the U.S. Food and Drug Administration for missing out the opportunities to mitigate and proactively prevent drug shortages in the U.S., according to the reports of the U.S. Government Accountability Office (GAO).

  • FDA safety effort necessary.  // Medical Marketing & Media;Feb2010, Vol. 45 Issue 2, p10 

    The article reports on the U.S. Government Accountability Office (GAO) study on the need for the Food and Drug Administration (FDA) to develop a comprehensive plan to prepare the Office of Surveillance and Epidemiology (OSE) to take over additional regulatory authorities from the Office of New...

  • FDA Questioned by Other Feds on High-Risk Devices. Reed, Vita // Orange County Business Journal;4/25/2011, Vol. 34 Issue 17, p65 

    The article reports that the approval of U.S. Food and Drug Administration (FDA) to certain high-risk medical devices such as pacemakers and hip joints, has been criticized by the Government Accountability Office (GAO), which states that the high-risk devices are approved without sufficient...

  • DRUG SAFETY: FDA Has Begun Efforts to Enhance Postmarket Safety, but Additional Actions Are Needed.  // GAO Reports;12/9/2009, preceding p1 

    The article discusses the findings of the U.S. Government Accountability Office (GAO) on the oversight of postmarket drug safety by the Food and Drug Administration (FDA). GAO claims that FDA has started to address concerns in its postmarket drug safety management. GAO also admires FDA's move to...

  • FOOD SAFETY: FDA Should Strengthen Its Oversight of Food Ingredients Determined to Be Generally Recognized as Safe (GRAS). Shames, Lisa // GAO Reports;3/5/2010, preceding p1 

    The article examines the oversight of the U.S. Food and Drug Administration on generally recognized as safe (GRAS) substances, by the Government Accountability Office (GAO). It was found that its oversight process does not ensure the safety of GRAS determinations. The agency does not issue...

  • New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts: GAO-07-49. Aronovitz, Leslie G. // GAO Reports;12/19/2006, p1 

    Drug development is complex and costly, requiring the testing of numerous chemical compounds for their potential to treat disease. Before a new drug can be marketed in the United States, a new drug application (NDA), which includes scientific and clinical data, must be approved by the Food and...

Share

Read the Article

Other Topics